Related references
Note: Only part of the references are listed.A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole
Kyle John Wilby
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2018)
Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?
Monica Fung et al.
CLINICAL INFECTIOUS DISEASES (2018)
Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity
M. -P. Ledoux et al.
JOURNAL DE MYCOLOGIE MEDICALE (2018)
Isavuconazole for treatment of rare invasive fungal diseases
Oliver A. Cornely et al.
MYCOSES (2018)
In vitro susceptibility of cryptic species of Aspergillus fumigatus to isavuconazole, itraconazole and voriconazole by means of E-test
Iker Falces-Romero et al.
REVISTA IBEROAMERICANA DE MICOLOGIA (2018)
Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation
Galen M. Kabulski et al.
TRANSPLANT INFECTIOUS DISEASE (2018)
Two Phase 1, Open-Label, Mass Balance Studies to Determine the Pharmacokinetics of C-14-Labeled Isavuconazonium Sulfate in Healthy Male Volunteers
Robert Townsend et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis
Teclegiorgis Gebremariam et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
New pharmacological opportunities for the treatment of invasive mould diseases
Marie-Pierre Ledoux et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Future Research Priorities in Fungal Resistance
Matthew W. McCarthy et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects
Takao Yamazaki et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects
Takao Yamazaki et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Pharmacokinetic Interaction Between Isavuconazole and a Fixed-Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects
Takao Yamazaki et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
Robert Townsend et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults
Andreas H. Groll et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects
Amit Desai et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis
Helen Box et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Successful Isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome
Yasmina Ahmed et al.
AMERICAN JOURNAL OF OTOLARYNGOLOGY (2016)
Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis
Vidmantas Petraitis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis
Nathan P. Wiederhold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
Laura L. Kovanda et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
Amit Desai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi
Amit Desai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In Vitro Activity of Isavuconazole against Rasamsonia Species
J. Steinmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Real-Life Use of Isavuconazole in Patients Intolerant to Other Azoles
Eloy E. Ordaya et al.
CLINICAL INFECTIOUS DISEASES (2016)
Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis
Matt Shirley et al.
DRUGS (2016)
Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH
Anne Schmitt-Hoffmann et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2016)
Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints
Laura L. Kovanda et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan A. Maertens et al.
LANCET (2016)
Isavuconazole: an azole active against mucormycosis
Emmanuel Roilides et al.
LANCET INFECTIOUS DISEASES (2016)
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Francisco M. Marty et al.
LANCET INFECTIOUS DISEASES (2016)
Role of isavuconazole in the treatment of invasive fungal infections
Dustin T. Wilson et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Isavuconazole: A New Option for the Management of Invasive Fungal Infections
Natasha N. Pettit et al.
ANNALS OF PHARMACOTHERAPY (2015)
Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model
Seyedmojtaba Seyedmousavi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation Study
Oliver A. Cornely et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
Marisa H. Miceli et al.
CLINICAL INFECTIOUS DISEASES (2015)
In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs
Hamid Badali et al.
MYCOSES (2015)
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent
Jeffrey M. Rybak et al.
PHARMACOTHERAPY (2015)
Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for the Cryptococcus neoformans-Cryptococcus gattii Species Complex Using the CLSI M27-A3 Broth Microdilution Method
A. Espinel-Ingroff et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatus
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds
Michael A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections
Joanne Livermore et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Newer antifungal agents
Ozden Turel
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2011)
Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557
A. Schmitt-Hoffmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing
Susanne Perkhofer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect
Peter A. Warn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species
George R. Thompson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi
Gloria M. Gonzalez
MEDICAL MYCOLOGY (2009)
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species
Jesus Guinea et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates
H. Seifert et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.
PA Warn et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers
A Schmitt-Hoffmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers
A Schmitt-Hoffmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Share Paper
